Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook525
Review of precision cancer medicine: Evolution of the treatment paradigm306
Immunotherapy for pancreatic cancer: A 2020 update251
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis178
The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target160
MYC as a target for cancer treatment155
Biomarkers for immunotherapy response in head and neck cancer142
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?136
KRAS: From undruggable to a druggable Cancer Target127
How did lomustine become standard of care in recurrent glioblastoma?112
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies106
The role of autophagy in resistance to targeted therapies87
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis85
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer85
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma85
Targeting FGFR inhibition in cholangiocarcinoma83
Microsatellite instability in Gastric Cancer: Between lights and shadows83
MEK inhibitor resistance mechanisms and recent developments in combination trials82
BAP1: Not just a BRCA1-associated protein82
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal80
Treatment landscape of metastatic pancreatic cancer79
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures78
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality77
Cancer and COVID-19: Unmasking their ties75
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer74
EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins73
Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities70
Global challenges and policy solutions in breast cancer control69
Current standards and future perspectives in adjuvant treatment for biliary tract cancers69
Challenges in the treatment of gastric cancer in the older patient68
HER2-positive advanced breast cancer treatment in 202065
The role of exosomes in metastasis and progression of melanoma62
Targeting ARID1A mutations in cancer61
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy59
Evolving role of regorafenib for the treatment of advanced cancers58
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management58
SARS-CoV-2 and cancer: Are they really partners in crime?58
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives55
Breast implant-associated anaplastic large cell lymphoma: A comprehensive review54
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application53
NRAS mutant melanoma: Towards better therapies53
Immunotherapy in non-small cell lung cancer harbouring driver mutations51
Parathyroid cancer: An update50
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping49
Melanoma brain metastases – Interdisciplinary management recommendations 202049
Thymic epithelial tumors: From biology to treatment47
How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement47
Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives43
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic43
Targeting brain metastases in breast cancer43
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials43
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs42
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis42
The force of HER2 – A druggable target in NSCLC?41
Cabozantinib: An evolving therapy for hepatocellular carcinoma40
Liquid biopsy in lymphoma: Molecular methods and clinical applications40
Roadmap to cure multiple myeloma39
Turning tumors from cold to inflamed to improve immunotherapy response39
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis39
Treatment strategies for patients with diffuse large B-cell lymphoma39
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials39
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis38
A basic review on systemic treatment options in WHO grade II-III gliomas38
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression38
Targeting HER2 heterogeneity in breast cancer38
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data37
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors37
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials35
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond35
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges35
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward34
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer34
Neurological complications of cancer immunotherapy33
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone33
Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer33
Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis32
Precision medicine in breast cancer: From clinical trials to clinical practice32
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?32
A review of retroperitoneal liposarcoma genomics31
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives31
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives30
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice30
The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence29
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus29
Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer29
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities29
Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review29
Accelerating drug development in breast cancer: New frontiers for ER inhibition28
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines28
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)28
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes28
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis28
Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis28
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials27
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications27
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges27
Current management of stage IV nasopharyngeal carcinoma without distant metastasis27
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities27
The promise of bispecific antibodies: Clinical applications and challenges27
Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future27
SELNET clinical practice guidelines for soft tissue sarcoma and GIST27
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines)27
Immunotherapy in cervix cancer26
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer26
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials26
A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification26
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers25
Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era24
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer24
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors24
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?24
Seroprevalence of SARS-CoV-2–specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data24
The current clinical landscape of personalized cancer vaccines23
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation23
Prognostic factors in patients with oligometastatic breast cancer – A systematic review22
Clinical trial data of Anti–PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review21
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis21
0.03733491897583